Early Parkinson's disease trial for new drug MT101-5
Part of Brain & nervous system clinical trials.
This study tests an investigational drug called MT101-5 for people with early Parkinson's disease. The goal is to see if it is safe and can help slow the progression of symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 30 and 79 years old.
- You must have been diagnosed with Parkinson's disease within the last 2 years.
- You must be in the early stages of Parkinson's (Hoehn and Yahr stage I or II).
- You must not be taking certain Parkinson's medications like levodopa or dopamine agonists, or if you are, you stopped them at least 60 days ago.
- You must be able to understand and follow the study plan and give your consent.
- Women who can become pregnant must use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IPS101A in people with advanced Parkinson's disease. It aims to see if the drug is safe and how well it works when standard treatments are no longer enough.
This trial tests an experimental drug called RO7568282 to see if it is safe and can help with early Parkinson's disease symptoms. It is for people who have been taking a stable dose of levodopa alone for at least two months.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.